Recursion Pharmaceuticals, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 2.32M3.96M10.18M39.84M44.58M58.84M
Cost of Revenue 48.27M42.59M45.24M
Gross Profit 2.32M3.96M10.18M-8.43M1.99M13.60M
Operating items
Research & Development 45.81M63.32M135.27M155.70M241.23M314.42M
Selling, General & Administrative 18.95M25.26M57.68M81.60M110.82M178.18M
Other Operating Expenses 48.27M42.59M45.24M
Operating Expenses 64.76M88.58M192.95M285.57M394.63M537.84M
Operating Income -62.44M-84.61M-182.78M-245.73M-350.06M-479.00M
EBIT -62.44M-84.61M-182.78M-245.73M-350.06M-479.00M
Non-operating items
Non Operating Income 0.56M-2.39M-3.70M6.25M17.93M14.22M
Net income details
EBT -62.44M-84.61M-186.48M-239.48M-332.13M-464.79M
Tax Provisions -4.06M-1.13M
Profit After Tax -61.88M-87.01M-186.48M-239.48M-328.07M-463.66M
Income from Continuing Operations -62.44M-84.61M-186.48M-239.48M-328.07M-463.66M
Consolidated Net Income -62.44M-84.61M-186.48M-239.48M-328.07M-463.66M
Income towards Parent Company -62.44M-84.61M-186.48M-239.48M-328.07M-463.66M
Net Income towards Common Stockholders -62.44M-84.61M-186.48M-239.48M-328.07M-463.66M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 159.91M168.99M189.56M216.62M286.64M
Shares Outstanding (Diluted Average) 21.57M21.78M125.35M175.54M207.85M274.21M
EBITDA -62.44M-84.61M-182.78M-245.73M-350.06M-479.00M
Tax Rate 1.22%0.24%